Biocon Biologics

Matt Erick, Chief Commercial Officer for Advanced Markets at Biocon Biologics, recently spoke at the Association for Value-Based Cancer Care (AVBCC) Annual Summit in New York City this October. The AVBCC Summit brings together oncology care professionals and experts from diverse fields, providing a platform for collaborative insights. In a panel discussion, Matt highlighted the need for “sustainable pricing that encourages biosimilar and generic adoption while ensuring companies remain viable and competitive in the market.” #AVBCC2024 #Biosimilars #OncologyCare #SustainablePricing #BioconBiologicsNorthAmerica

Today, on #WorldPsoriasisDay, we stand with millions of people living with psoriasis. Understanding this chronic condition begins with awareness, empathy, and knowledge. Psoriasis is more than skin-deep; it impacts physical and emotional health. At Biocon Biologics, we’re committed to advancing innovative treatments that help patients manage their condition and lead healthier lives. Together, let’s build a future where understanding leads to better care and support for those affected by psoriasis.  #UnderstandingPsoriasis #BioconBiologics #WorldPsoriasisDay2024 #HealthcareInnovation

Biocon created history in December 2017 when its biosimilar Trastuzumab co-developed with long-term partner Mylan (now Viatris) won approval from the U.S. Food and Drug Administration (FDA). Ogivri™, a drug for treating aggressive forms of breast and gastric cancers, is the first biosimilar Trastuzumab to be approved in the U.S. This breakthrough, which also made Biocon the first Indian company to have a biosimilar approved in the U.S., is a significant step ahead in the Company’s mission to become a global biosimilars leader and empowering thousands of patients worldwide to continue their fight against cancer with dignity and strength. #BioconBiologics #Trastuzumab #BreastCancer #BreastCancerAwareness

Given the significant savings that biosimilars offer to the U.S. healthcare system, we are witnessing favorable changes in the regulatory and policy landscape in the country. These changes are gradually reducing barriers to entry, making biosimilars more attractive and accessible. Download the Report: https://bit.ly/47WvTBg Seema Shah Ahuja Gopal Rao Saurabh Narain Susheel Umesh Pritha Paul Rahul Kapur Dr. Shivani M. Nimish Shah Matt Erick Sandeep Athalye #CancerCare #AffordableHealthcare #Biosimilars #HealthcareForAll #BioconBiologics #ClarivateReport

Joshua Salsi, Head of North America at Biocon Biologics, participated in a panel at the Association for Accessible Medicines GrX+Biosims 2024 Conference. Joined by industry leaders, they reviewed the state of the biosimilars industry, discussed progress, and covered the challenges and opportunities to achieving long-term market sustainability. #grxbiosims2024 #BioconBiologics

Excited to announce that Biocon Chairperson Kiran Mazumdar Shaw has been honored with the IKP@25 Shapers Award at #IKMC2024 for her invaluable and steadfast support of over 25 years to IKP Knowledge Park which has been a driving force in shaping India's #innovation landscape.

Earlier this month, our teams from the Czech Republic, Slovakia, and Croatia united for the first time in beautiful Opatija, Croatia, for a highly productive meeting focused on expanding access to biosimilar medicines and planning future growth strategies. We are immensely proud of every team member’s dedication and hard work—our success truly reflects your commitment! #BioconBiologics #BioconBiologicsEurope #Biosimilars #Growth #TeamSuccess #BuildingTogether

Biocon began developing its biosimilar Trastuzumab in 2008, offering a cost-effective, high-quality treatment for HER2-positive, metastatic breast cancer and gastric cancer. A rigorous clinical trial established its similarity to the reference product, Herceptin®, and in 2013, following a successful regulatory submission to the Drug Controller General of India, it became the first biosimilar Trastuzumab to be approved anywhere in the world. Since then, it has profoundly transformed cancer treatment globally. #BioconBiologics #Trastuzumab #BreastCancer #BreastCancerAwareness

Alert: Seats are filling fast! If you are ready to make your mark, here’s your moment— admissions for Batch 28 of the Biocon KGI Certificate in Biosciences are open. To apply, click https://bit.ly/4gcBjM0 For more information, click https://bit.ly/3Zu1Ez8 #admissions #applynow #biosciences #biotechnology #biochemistry #careers #engineers #freshers #genetics #lifesciences #microbiology #opportunities #pharmacy #technology

Anita Krishnan, Head of Analytical Sciences at Biocon Biologics, spoke at the GrX+Biosims 2024 Conference this week, hosted by the Association for Accessible Medicines. She was part of an exciting panel about non-clinical immunogenicity studies and the multi-attribute method (MAM), a streamlined workflow to bring safe, high-quality medicines to market faster. #grxbiosims2024 #BioconBiologics #MAM #BioconBiologicsNorthAmerica